Fractyl HealthGUTS
GUTS
About: Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.
Employees: 109
0
Funds holding %
of 7,316 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
18% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 17
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
0% more funds holding
Funds holding: 65 [Q4 2024] → 65 (+0) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 3 (+0) [Q1 2025]
2.86% less ownership
Funds ownership: 53.85% [Q4 2024] → 50.99% (-2.86%) [Q1 2025]
44% less capital invested
Capital invested by funds: $53.4M [Q4 2024] → $29.7M (-$23.7M) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$12
705%
upside
Avg. target
$12
705%
upside
High target
$12
705%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Canaccord Genuity | 705%upside $12 | Buy Initiated | 15 Apr 2025 |
Financial journalist opinion
Based on 3 articles about GUTS published over the past 30 days
Neutral
GlobeNewsWire
3 weeks ago
Fractyl Health Reports Positive 3-Month REVEAL-1 Cohort Data Showing Revita® Sustained Weight Loss After GLP-1 Discontinuation, Supporting its Potential as a First-in-Class Weight Maintenance Therapy
12 of 13 participants maintained or lost weight at 3 months, with 6 of 13 losing additional weight after stopping GLP-1 therapy and undergoing Revita procedure
Neutral
GlobeNewsWire
3 weeks ago
Fractyl Health Presents New Data at the American Diabetes Association's 85th Scientific Sessions Demonstrating its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform Prevents Obesity and Type 2 Diabetes in Preclinical Models
New findings demonstrated that a single dose of Rejuva was well tolerated in healthy animals, with no evidence of toxicity
Neutral
GlobeNewsWire
3 weeks ago
Fractyl Health Reinforces Intellectual Property Leadership in Metabolic Disease with Two New U.S. Patents Directed to Duodenal Resurfacing
Robust intellectual property portfolio, built over more than a decade, designed to protect core innovations for treating metabolic diseases New U.S. patents strengthen Fractyl's leadership in metabolic innovation by expanding its patent coverage of duodenal resurfacing, including thermal and non-thermal electrical energy applications BURLINGTON, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced that the United States Patent and Trademark Office has issued two new patents that further strengthen the Company's extensive intellectual property (IP) portfolio protecting its duodenal resurfacing innovations.
Neutral
GlobeNewsWire
1 month ago
Fractyl Health to Present New Preclinical Data from its Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Platform at the American Diabetes Association's 85th Scientific Sessions
BURLINGTON, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will present a poster of new preclinical data from its Rejuva Smart GLP-1 pancreatic gene therapy platform at the American Diabetes Association's (ADA) 85th Scientific Sessions being held June 20-23, 2025, in Chicago, Illinois.
Neutral
GlobeNewsWire
1 month ago
Fractyl Health and Bariendo Sign Letter of Intent to Prepare for Potential Offering of Revita® Across its Bariatric and Metabolic Endoscopy Centers Nationwide
Collaboration is designed to implement a highly scalable clinical pathway for Revita in post GLP-1 weight maintenance, pending FDA approval, potentially benefiting millions of eligible patients Rising interest from patients and payers for an off-ramp from GLP-1 drugs is fueling significant demand for endoscopic alternatives designed to restore health rather than manage disease BURLINGTON, Mass. and SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), and Bariendo Inc. (Bariendo), the first all-in-one obesity care platform with cost-effective and durable endoscopic treatments for the rising obesity epidemic, today announced the signing of a non-binding Letter of Intent (the LOI) to explore a future collaboration centered on Fractyl's investigational Revita procedure as a durable off-ramp for weight maintenance following GLP-1 drug discontinuation.
Neutral
GlobeNewsWire
1 month ago
Fractyl Health Advances Rejuva® Gene Therapy Platform with Submission of First Clinical Trial Application Module in Europe for RJVA-001 in Type 2 Diabetes
First-in-human study will evaluate safety, tolerability, and early efficacy of a one-time, pancreas-targeted smart GLP-1 TM gene therapy for patients with inadequately controlled T2D and obesity
Neutral
GlobeNewsWire
1 month ago
Fractyl Health Unveils New Rejuva® Smart GLP-1™ Pancreatic Gene Therapy Preclinical Data Highlighting Durable Potency and Safety with Limited Systemic GLP-1 Exposure at ASGCT 2025
Data suggests that single dose of RJVA-001 leads to durable metabolic improvements with low systemic GLP-1 exposure in db/db mouse model of T2D— potentially simultaneously addressing durability, adherence, and tolerability challenges seen with current GLP-1 drugs
Neutral
Business Wire
2 months ago
Forge Biologics Announces AAV Development and cGMP Manufacturing Relationship with Fractyl Health to Advance Their Gene Therapy Platform for Patients with Metabolic Diseases
COLUMBUS, Ohio--(BUSINESS WIRE)--Forge Biologics (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced an AAV development and manufacturing agreement to help advance Fractyl Health's Rejuva* pancreatic gene therapy platform for the treatment of patients with obesity and type 2 diabetes (T2D). "We developed our FUEL™ platform to provide developers like Fractyl with a more efficient and scalable manufacturing solution to help.
Neutral
Seeking Alpha
2 months ago
Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript
Fractyl Health, Inc. (NASDAQ:GUTS ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Brian Luque - Head of Investor Relations and Corporate Development Harith Rajagopalan - Co Founder and Chief Executive Officer Lisa Davidson - Chief Financial Officer and Treasurer Conference Call Participants Avi Novick - Morgan Stanley Michael DiFiore - Evercore ISI Whitney Ijem - Canaccord Genuity Operator Good afternoon. And welcome to Fractyl Health's First Quarter 2025 Financial Results and Business Updates Call.
Neutral
GlobeNewsWire
2 months ago
Fractyl Health Announces First Quarter 2025 Financial Results and Business Updates
REVEAL-1 Cohort 3-month open-label data update expected in June 2025; early clinical signals reinforce Revita's potential to maintain weight loss after GLP-1 discontinuation in the real world REMAIN-1 Midpoint Cohort data expected in Q3 2025; first randomized data on post-GLP-1 weight maintenance REMAIN-1 Pivotal Cohort has completed enrollment ahead of schedule; 6-month primary endpoint data anticipated in H2 2026 Rejuva gene therapy platform advancing toward first-in-human studies; first CTA module submission for RJVA-001 expected in June 2025 Conference call today at 4:30 p.m. ET BURLINGTON, Mass.
Charts implemented using Lightweight Charts™